Deutsch English Français

Contact

EP1280552

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1280552

EP1280552 - METHODS OF TREATING SKIN CANCER USING COMPOSITIONS COMPRISING AN INHIBITOR OF ENDOTHELIN RECEPTOR B [Right-click to bookmark this link]
Former [2003/06]	COMPOSITIONS AND METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AN INHIBITOR OF ENDOTHELIN RECEPTOR ACTIVITY
	[2007/06]
Status	No opposition filed within time limit Status updated on 20.06.2008 Database last updated on 18.11.2024
Most recent event Tooltip	03.10.2008	Change - representative	published on 05.11.2008 [2008/45]
Applicant(s)	For all designated states CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 East California Boulevard Mail Code 210-85 Pasadena, CA 91125 / US
	[N/P]
Former [2007/33]	For all designated states CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 East California Boulevard, Mail Code 210-85 Pasadena, CA 91125 / US
Former [2003/06]	For all designated states California Institute of Technology 1200 East California Boulevard, Mail Code 210-85 Pasadena, CA 91125 / US
Inventor(s)	01 / PATTERSON, Paul, H. 1410 La Solana Drive Altadena, CA 91001 / US
	02 / LE COUTRE-LAHAV, Ronit Chemin du Fau-blanc 32 1009 Pully / CH
	[2007/21]
Former [2003/06]	01 / PATTERSON, Paul, H. 1410 La Solana Drive Altadena, CA 91001 / US
	02 / LAHAV, Ronit Inst. De Pathologie, CHUV, Rue du Bugnon 25 CH1011 Lausanne / CH
Representative(s)	Howard, Paul Nicholas, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2008/45]	Howard, Paul Nicholas, et al Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA / GB
Former [2006/26]	Howard, Paul Nicholas, et al Carpmaels & Ransford, 43-45 Bloomsbury Square London WC1A 2RA / GB
Former [2003/06]	Walton, Seán Malcolm, et al MEWBURN ELLIS, York House, 23 Kingsway London WC2B 6HP / GB
Application number, filing date	00946969.3	29.06.2000
	[2003/06]
	WO2000US18215
Priority number, date	US19990141450P	29.06.1999 Original published format: US 141450 P
	US19990404626	23.09.1999 Original published format: US 404626
	[2003/06]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO0100198
	Date:	04.01.2001
	Language:	EN
	[2001/01]
	Type:	A2 Application without search report
	No.:	EP1280552
	Date:	05.02.2003
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 04.01.2001 takes the place of the publication of the European patent application.
	[2003/06]
	Type:	B1 Patent specification
	No.:	EP1280552
	Date:	15.08.2007
	Language:	EN
	[2007/33]
Search report(s)	International search report - published on:	EP	31.10.2002
Classification	IPC:	A61K38/06, A61P35/00	[2007/06]
	CPC:	A61K38/06 (EP,US); A61K47/50 (EP,US); A61P35/00 (EP); G01N33/574 (EP,US); G01N2333/5754 (EP,US)
	Former IPC [2003/06]	A61K45/00
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2003/06]
Title	German:	VERFAHREN ZUR BEHANDLUNG VON HAUTKREBS MITTELS ZUSAMMENSETZUNGEN, DIE EINEN ENDOTHELINREZEPTOR-B-HEMMER ENTHALTEN	[2007/06]
	English:	METHODS OF TREATING SKIN CANCER USING COMPOSITIONS COMPRISING AN INHIBITOR OF ENDOTHELIN RECEPTOR B	[2007/06]
	French:	PROCEDE DE TRAITEMENT DU CANCER DE LA PEAU AVEC DES COMPOSITIONS CONTENANT UN INHIBITEUR DU RECEPTEUR DE L'ENDOTHELINE DE TYPE B	[2007/06]
	Former [2003/06]	ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON KREBS MITTELS ZUSAMMENSETZUNGEN, DIE EINEN ENDOTHELINREZEPTORAKTIVITÄTSHEMMER ENTHALTEN
	Former [2003/06]	COMPOSITIONS AND METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AN INHIBITOR OF ENDOTHELIN RECEPTOR ACTIVITY
	Former [2003/06]	COMPOSITIONS ET PROCEDE DE TRAITEMENT DU CANCER AVEC DES COMPOSITIONS CONTENANT UN INHIBITEUR DE L'ACTIVITE DU RECEPTEUR DE L'ENDOTHELINE
Entry into regional phase	23.01.2002	National basic fee paid
	23.01.2002	Designation fee(s) paid
	23.01.2002	Examination fee paid
Examination procedure	26.01.2001	Request for preliminary examination filed International Preliminary Examining Authority: EP
	23.01.2002	Amendment by applicant (claims and/or description)
	23.01.2002	Examination requested [2003/06]
	23.04.2002	Observations by third parties
	24.02.2004	Despatch of a communication from the examining division (Time limit: M06)
	08.10.2004	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	17.12.2004	Reply to a communication from the examining division
	17.01.2006	Despatch of a communication from the examining division (Time limit: M04)
	26.05.2006	Reply to a communication from the examining division
	25.07.2006	Despatch of a communication from the examining division (Time limit: M02)
	07.08.2006	Reply to a communication from the examining division
	01.02.2007	Communication of intention to grant the patent
	04.05.2007	Fee for grant paid
	04.05.2007	Fee for publishing/printing paid
Opposition(s)	16.05.2008	No opposition filed within time limit [2008/30]
Request for further processing for:	17.12.2004	Request for further processing filed
	17.12.2004	Full payment received (date of receipt of payment) Request granted
	04.01.2005	Decision despatched
Fees paid	Renewal fee
	24.06.2002	Renewal fee patent year 03
	31.12.2003	Renewal fee patent year 04
	05.07.2004	Renewal fee patent year 05
	21.06.2005	Renewal fee patent year 06
	28.06.2006	Renewal fee patent year 07
	29.06.2007	Renewal fee patent year 08
	Penalty fee
	Additional fee for renewal fee
	30.06.2003	04 M06 Fee paid on 31.12.2003
	30.06.2004	05 M06 Fee paid on 05.07.2004
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	FI	15.08.2007
	[2008/10]
Cited in	International search	[X]WO9841206 (BASF AG [DE], et al) [X] 1-3,5,6,9,11-22 * see in particular p. 2, l. 23-26; p.35, l. 21 - p. 38, l. 29. *;
		[E]WO0036918 (MARINE POLYMERS TECHNOLOGIES I [US]) [E] 1-6,8-11,13-22 * see in particular p. 51, table 1; examples 11B-14; p. 61, l. 16-19; claims 1, 4, 5 and 30. *;
		[PX] - LAHAV, RONIT ET AL, "An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (SEPT. 28, 1999) VOL. 96, NO. 20, PP. 11496-11500., XP001026099 [PX] 1-22 * see in particular the abstract and figures 2, 6 and 7. * DOI: http://dx.doi.org/10.1073/pnas.96.20.11496
		[DX] - KIKUCHI K ET AL, "DECREASED ETB RECEPTOR EXPRESSION IN HUMAN METASTATIC MELANOMA CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (1996), vol. 219, no. 3, ISSN 0006-291X, pages 734 - 739, XP002931328 [DX] 1-5,8,10,12-22 * see in particular p. 737, figure 2; p. 738, l. 9-10. * DOI: http://dx.doi.org/10.1006/bbrc.1996.0303
		[X] - GIRALDI T ET AL, "PRIMARY TUMOR GROWTH AND FORMATION OF SPONTANEOUS LUNG METASTASES IN MICE BEARING LEWIS CARCINOMA TREATED WITH PROTEINASE INHIBITORS.", ANTICANCER RES, (1984) 4 (4-5), 221-224., XP000646515 [X] 1-3,5,8-22 * see in particular the abstract; p. 223, table I and last paragraph. *
		[X] - TUERK, I. ET AL, "Inhibition of growth of prostate cancer cell lines by endothelin receptor antagonists.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, URL: STN, XP002184315 [X] 1-3,5,6,8-22 * abstract *
		[ ] - JOURNAL OF UROLOGY, (APRIL, 1999) VOL. 161, NO. 4 SUPPL., PP. 62. MEETING INFO.: 94TH ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION, INC. DALLAS, TEXAS, USA MAY 1-6, 1999 AMERICAN UROLOGICAL ASSOCIATION.
		[X] - CARDUCCI, MICHAEL A. (1) ET AL, "Endothelin receptor antagonist, ABT-627, for prostate cancer: Initial trial results.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, URL: STN, XP002184316 [X] 1-3,5,6,8-22 * abstract *
		[ ] - JOURNAL OF UROLOGY, (APRIL, 1999) VOL. 161, NO. 4 SUPPL., PP. 176. MEETING INFO.: 94TH ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION, INC. DALLAS, TEXAS, USA MAY 1-6, 1999 AMERICAN UROLOGICAL ASSOCIATION.
		[X] - CARDUCCI, M. A. (1) ET AL, "Phase I clinical results of ABT - 627, an endothelin receptor antagonist, for refractory adenocarcinomas.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, URL: STN, XP002184317 [X] 1-3,5-22 * abstract *
		[ ] - PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 91. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICAN A
		[X] - KROODSMA J.M. ET AL, "[Endothelins: Possibly a new approach to pharmacotherapy of cardiovascular diseases, renal diseases and oncological conditions]. ENDOTHELINEN: MOGELIJK EEN NIEUW FARMACOLOGISCH AANGRIJPINGSPUNT BIJ HART- EN VAATZIEKTEN, NIERZIEKTEN EN ONCOLOGISCHE AANDOENINGEN.", NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE, (1997) 141/38 (1806-1810)., XP002070362 [X] 1-3,5,6,8-22 * see the English abstract *
		[X] - MORAITIS, S. ET AL, "Endothelin expression and responsiveness in human ovarian carcinoma cell lines.", EUROPEAN JOURNAL OF CANCER, (1997) VOL. 33, NO. 4, PP. 661-668., XP004282572 [X] 1-3,5,7,9,11,13-22 * see in particular the abstract; p. 665, left paragraph, l. 9-19; p. 666, figures 6 and 7. * DOI: http://dx.doi.org/10.1016/S0959-8049(97)00012-9
		[X] - JANUS, T. J. ET AL, "ABT-627, endothelin-receptor antagonist, for advanced cancer: Phase I pharmacokinetic results.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 90-91. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICA, XP001026083 [X] 1-3,5-7,9,11,13-22 * abstract *
	other	- NELSON J.B. ET AL, "ENDOTHELIN-1 PRODUCTION AND DECREASED ENDOTHELIN B RECEPTOR EXPRESSION", CANCER RESEARH, (19960215), vol. 56, no. 4, pages 663 - 668, XP001026084
		- NELSON J.B. ET AL, "IDENTIFICATION OF ENDOTHELIN-1 IN THE PATHOPHYSIOLOGY OF METASTATICADENOCARCINOMA OF THE PROSTATE", NATURE MEDICINE, (199909), vol. 1, no. 9, pages 944 - 949, XP002919559 DOI: http://dx.doi.org/10.1038/nm0995-944
		- KROODSMA J.M.; RABELINK A.J., "ENDOTHELINEN: MOGELIJK EEN NIEUW FARMACOLOGISCH AANGRIJPINGSPUNT BIJ HART- EN VAATZIEKTEN, NIERZIEKTEN EN ONCOLOGISCHE AANDOENINGEN", NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE, (19970920), vol. 141, no. 38, pages 1806 - 1810, XP002070362
		- KROODSMA J.M.; RABELINK A.J., "Endothelins: possibly a new pharmacological starting point in cardiovascular disease, kidney disease and oncological conditions", NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE (ENGLISH TRANSLATION), (19970920), vol. 141, no. 38, pages 1 - 3, XP002909157
		- SYMPOSIUM - ENDOTHELIN INHIBITORS: EXPLORING NOVEL THERAPEUTICS, WASHINGTON DC, USA, (19990607), page 1, XP002909158
		- BOVEN E., AMERICAN SOCIETY OF CLINICAL ONCOLOGY - 35TH ANNUAL MEETING (PART 1), ATLANTA, GA, USA, (19990515), page 1, XP002909159
		- MCKINNON C., AMERICAN SOCIETY OF CLINICAL ONCOLOGY - 35TH ANNUAL MEETING (PART IV), ATLANTA GA, USA, (19990515), page 1, XP002909160
		- ADENIYI A., AMERICAN UROLOGICAL ASSOCIATION - 94TH ANNUAL MEETING, DALLAS, USA, (19990501), page 1, XP002909161
		- BOVEN E., "Meeting Report ASCO", IDRUGS, ATALANTA GA, USA, (1999), vol. 2, no. 7, pages 617 - 619, XP002909162
		- MCKINNON C., "Topoisomerase inhibitors and other new agents", IDRUGS, (1999), vol. 2, no. 7, pages 629 - 631, XP002909163
		- ADENIYI A., "Meeting report", IDRUGS, DALLAS, USA, (1999), vol. 2, no. 7, pages 656 - 658, XP002909164

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p